The histone deacetylase inhibitor vaproic acid induces cell growth arrest in hepatocellular carcinoma cells via suppressing notch signaling

Journal of Cancer

Volumn 6, Issue 10, 2015, Pages 996-1004

  Sun, Guangchun ^a   Mackey, Lily V ^c   Coy, David H ^c   Yu, Cui Yun ^b,c   Sun, Lichun ^a,b,c  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

HDAC inhibitor; Hepatocellular carcinoma; Notch signaling; Receptor targeting; Valproic acid

Indexed keywords

ACETYLATED HISTONE 4; BOMBESIN RECEPTOR; CAMPTOTHECIN; DIBENZAZEPINE DERIVATIVE; DIMETHYL SULFOXIDE; G PROTEIN COUPLED RECEPTOR; GELATINASE A; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; HORMONE RECEPTOR BLOCKING AGENT; ICN1 PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PROTEIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P63; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; TRANSCRIPTION FACTOR HES 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; UVOMORULIN; VALPROIC ACID;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL CYCLE ASSAY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL STRUCTURE; CONCENTRATION RESPONSE; DOWN REGULATION; GENE OVEREXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84947801386     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12135     Document Type: Article

References (44)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013; 47 (Suppl): S2-6.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118-27.
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264-73.
5. Moeini A, Cornella H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012; 1: 83-93.
6. Morell CM, Fiorotto R, Fabris L, Strazzabosco M. Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. Clin Res Hepatol Gastroenterol. 2013; 37: 447-54.
7. Villanueva A, Llovet JM. Liver cancer in 2013: Mutational landscape of HCC-the end of the beginning. Nat Rev Clin Oncol. 2014; 11: 73-4.
8. Noh JH, Bae HJ, Eun JW, Shen Q, Park SJ, Kim HS, et al. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res. 2014; 74: 1728-38.
9. Venturelli S, Berger A, Bocker A, Busch C, Weiland T, Noor S, et al. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One. 2013; 8: e73097.
10. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist. 2007; 12: 535-42.
11. Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 2010; 80: 690-701.
12. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, et al. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol. 2009; 50: 969-79.
13. Franko-Tobin LG, Mackey LV, Huang W, Song X, Jin B, Luo J, et al. Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist. 2012; 17: 220-32.
14. Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, et al. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget. 2013; 4: 1618-31.
15. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008; 34: 206-22.
16. Morell CM, Strazzabosco M. Notch signaling and new therapeutic options in liver disease. J Hepatol. 2014; 60: 885-90.
17. Bogaerts E, Heindryckx F, Vandewynckel YP, Van Grunsven LA, Van Vlierberghe H. The roles of transforming growth factor-beta, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol. 2014; 44: 1015-22.
18. Geisler F, Strazzabosco M. Emerging roles of Notch signaling in liver disease. Hepatology. 2015; 61: 382-92.
19. Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B, et al. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology. 2013; 57: 1607-19.
20. Ahn S, Hyeon J, Park CK. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013; 12: 286-94.
21. Ning L, Wentworth L, Chen H, Weber SM. Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res. 2009; 1: 358-66.
22. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A, et al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int. 2007; 27: 997-1007.
23. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 2012; 143: 1660-9.
24. Gao J, Dong Y, Zhang B, Xiong Y, Xu W, Cheng Y, et al. Notch1 activation contributes to tumor cell growth and proliferation in human hepatocellular carcinoma HepG2 and SMMC7721 cells. Int J Oncol. 2012; 41: 1773-81.
25. Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011; 208: 1963-76.
26. Wang C, Qi R, Li N, Wang Z, An H, Zhang Q, et al. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J Biol Chem. 2009; 284: 16183-90.
27. Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res. 2003; 63: 8323-9.
28. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002; 13: 1-13.
29. Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. 2012; 110: 739-48.
30. Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011; 16: 835-43.
31. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist. 2007; 12: 942-51.
32. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H. Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res. 2008; 148: 31-7.
33. Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, et al. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci. 2011; 88: 418-24.
34. Tsai C, Leslie JS, Franko-Tobin LG, Prasnal MC, Yang T, Vienna Mackey L, et al. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemo-therapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet. 2013; 288: 393-400.
35. Li X, Zhu Y, He H, Lou L, Ye W, Chen Y, et al. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells. Biochem Biophys Res Commun. 2013; 436: 259-64.
36. Machado MC, Bellodi-Privato M, Kubrusly MS, Molan NA, Tharcisio T, Jr., de Oliveira ER, et al. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol. 2011; 9: 85-92.
37. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett. 2009; 285: 210-7.
38. Sun LC, Mackey LV, Luo J, Fuselier JA, Coy DH. Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol. 2008; 2: 491-9.
39. Sun L, Sun G, Yu Y, Coy DH. Is Notch Signaling a Specific Target in Hepatocellular Carcinoma? Anticancer Agents Med Chem. 2015. [Epob ahead of print].
40. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57: 821-9.
41. Hu L, Xue F, Shao M, Deng A, Wei G. Aberrant expression of Notch3 predicts poor survival for hepatocellular carcinomas. Biosci Trends. 2013; 7: 152-6.
42. Wang F, Zhou H, Yang Y, Xia X, Sun Q, Luo J, et al. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep. 2012; 27: 1170-6.
43. Matsuda Y, Wakai T, Kubota M, Osawa M, Hirose Y, Sakata J, et al. Valproic acid overcomes transforming growth factor-beta-mediated sorafenib resistance in hepatocellular carcinoma. Int J Clin Exp Pathol. 2014; 7: 1299-313.
44. Sun LC, Coy DH. Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv. 2011; 8: 2-10.